Chris Farina

Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Their core competencies include chemical synthesis biochemistry, cell biology, and pharmacology. The focus of its company is on the development of unique chemical entities that operate by new cellular mechanisms. Its understanding of the molecular events that control the growth, replication, and apoptosis of human cells is becoming increasingly sophisticated. They intend to translate new knowledge of such pathways, and their misregulation in disease, into signaling-based targeted therapeutics.